NCT03952481

Effect of Lifitegrast 5% on Tear Film Markers

Improvement in Markers of Tear Film Instability After Initiation of Lifitegrast 5% Ophthalmic Solution: A Prospective Interventional Study

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.

Conditions

• Dry Eye
• Dry Eye Syndromes
• Dry Eyes Chronic

Interventions

Type	Name	Description
DRUG	Lifitegrast 5% Ophthalmic Solution	Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.

Timeline

• Start date: 2021-03-01
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2019-05-16
• Last updated: 2021-02-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study